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Background: Pro-inflammatory stimuli, including cytokines like Interleukin-1β, Interleukin-6 and Interferon-γ, in the
brain have been proposed to exacerbate existing Alzheimer’s disease (AD) neuropathology by increasing
amyloidogenic processing of APP and promoting further Aβ accumulation in AD. On the other hand, anti-
inflammatory cytokines have been suggested to be neuroprotective by reducing neuroinflammation and clearing
Aβ. To test this hypothesis, we used adeno-associated virus serotype 1 (AAV2/1) to express an anti-inflammatory
cytokine, murine Interleukin-4 (mIL-4), in the hippocampus of APP transgenic TgCRND8 mice with pre-existing
plaques.
Results: mIL-4 expression resulted in establishment of an “M2-like” phenotype in the brain and was accompanied
by exacerbated Aβ deposition in TgCRND8 mice brains. No change in holo APP or APP C terminal fragment or
phosphorylated tau levels were detected in mIL-4 expressing CRND8 cohorts. Biochemical analysis shows increases
in both SDS soluble and insoluble Aβ. mIL-4 treatment attenuates soluble Aβ40 uptake by microglia but does not
affect aggregated Aβ42 internalization by microglia or soluble Aβ40 internalization by astrocytes.
Conclusions: Short term focal mIL-4 expression in the hippocampus leads to exacerbation of amyloid deposition
in vivo, possibly mediated by acute suppression of glial clearance mechanisms. Given that recent preclinical data
from independent groups indicate engagement of the innate immune system early on during disease
pathogenesis may be beneficial, our present study strongly argues for a cautious re-examination of unwarranted
side–effects of anti-inflammatory therapies for neurodegenerative diseases, including AD.
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Amyloid β (Aβ) plaques constitute a hallmark patho-
logical feature of Alzheimer’s disease (AD), the most
prevalent neurodegenerative disorder. Neuroinflamma-
tion has been hypothesized to play a pathogenic role in
the development of sporadic AD, particularly because
pro-inflammatory cytokines and chemokines colocalize
with neurodegenerative pathology in both AD patient
brains as well as in transgenic mouse models of AD type
pathology (reviewed in [1]). However, the placement of
the inflammatory response in AD neurodegenerative
cascade is still debated, with conflicting ideas of innate* Correspondence: tgolde@ufl.edu
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distribution, and reproduction in any mediumimmune activation either being the trigger, a homeo-
static response mechanism or a bystander phenomenon
associated with the disease pathology [2].
Anti-inflammatory cytokines, such as Interleukin (IL) -
4, lead to the suppression of pro-inflammatory responses
in macrophages, microglia, T cells, and astrocytes [3].
Anti-inflammatory cytokines are thought to enhance Aβ
degradation through phagocytosis and receptor-
mediated uptake leading to the abrogation of Aβ
induced cell death in APP transgenic mice [4,5] and pri-
mary glia [6]. Down regulation of IL-4 receptors contri-
butes to aging related cognitive impairment [7].
Consequently, IL-4 or minocycline treatment leads to
restored synaptic activity in rats following intracerebro-
ventricular infusion of Aβ [8]. However, emerging evi-
dence has also shown that activation of the innate
immune system may constitute a beneficial defensentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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our lab [10-12] and others [13-17] have demonstrated
that glial activation can effectively clear Aβ plaques. It is
generally thought that although a sustained inflamma-
tory response is neurotoxic, activation of the innate im-
mune system can indeed have a beneficial function by
clearing debris and possibly promoting repair.
In an effort to further understand the role of neuroin-
flammation on Aβ plaque pathology and specifically to
test the role of anti-inflammatory cytokines on Aβ
pathology, we utilized recombinant adeno-associated
virus serotype 1 (rAAV2/1) to overexpress murine IL-4
(mIL-4) in the hippocampus of Amyloid precursor pro-
tein (APP) transgenic mice with pre-existing amyloid
plaques. Our results show that mIL-4 expression
resulted in exacerbated Aβ deposition in APP transgenic
mice brains after 6 weeks of expression. Biochemical
analysis of mIL-4 overexpressing mice brains and
phagocytosis assays in primary murine glia suggests that
mIL-4 expression leads to increased Aβ levels possibly
as a result of reduced glia phagocytosis.
Results
To explore the role of anti-inflammatory cytokines in
regulating Aβ accumulation in the CNS, we have used
recombinant adeno-associated virus serotype 1 (rAAV2/1)
to express mIL-4 in the brains of APP transgenic
TgCRND8 mice. Recombinant AAV2 plasmids were pack-
aged in AAV serotype 1 capsid as described previously [10]
and rAAV2/1 viruses expressing mIL-4 or EGFP under the
control of the cytomegalovirus enhancer/chicken β-actin
promoter were used for further experiments. Adult
TgCRND8 mice were stereotaxically injected with AAV2/1
constructs (1x1013 particles/ml) into the CA layer of the
hippocampus at 4 months (after Aβ plaque deposition has
started) and were analyzed after 6 weeks (n=6 for rAAV1-
mIL-4; n=6 for rAAV1-EGFP). Immunohistochemical
analysis with anti-EGFP antibody shows that the viral
transgene is predominantly expressed in the hippocampal
CA neurons, neuronal projections in the cortex and thal-
amus, and some overlying cortical neurons following
6 week expression of AAV1-EGFP (Additional file 1: Figure
S1, A-I). No detectable expression was noted in the mid-
brain, olfactory bulb or cerebellum. In previous studies
AAV2/1-EGFP expression had minimal effects on amyloid
pathology or gliosis when compared to naïve uninjected
mice [10,18,19]; so, AAV1-EGFP injected animals were
used as the control cohort in this study. For adult injected
mice, the brain was coronally dissected 1 mm anterior and
posterior to the point of injection and used for subsequent
analysis. We did not observe any significant changes in
GFAP immunoreactive astrocytes (Figure 1, A-D) or Iba-1
reactive microglia (Figure 1, E-H) in the hippocampus of
mIL-4 expressing mice compared to control mice. A carefulquantification of the histological staining (GFAP and Iba-1)
in mouse hippocampus using “Positive Pixel Count” pro-
gram (Aperio, CA) showed that though mIL-4 expressing
mice had less microglial activation in and around the injec-
tion area there were no significant changes in either
astrocyte or microglial levels overall (Figure 1, I). Immuno-
blotting analysis with hippocampal lysates also showed es-
sentially unchanged astrogliosis profile in mIL-4 and
control cohorts (Figure 1, J-K). Analysis of mRNA from
injected mice hippocampus showed significantly increased
levels of mIL-4 (3.13 times over control) and mIL-10
(2.4 times over control) (Figure 1, L). No significant change
in levels of pro-inflammatory cytokines, TNF-α and IFN-γ,
or cd11b (data not shown) was seen. Furthermore, this was
accompanied by an increase in Arginase (4 times over con-
trol) (Figure 1, L), suggesting an establishment of an alter-
native “M2a” microglial phenotype [1,20]. Increased levels
of CD200R (4.2 times over control) was also noted, similar
to previous observations [21].
Analysis of plaque burden showed that there was a
33.5% increase in amyloid plaques in the hippocampus
of mIL-4 expressing mice compared to EGFP expressing
mice (Figure 2, A-E). There was a concomitant increase
in insoluble Aβ levels by biochemical analysis - 41% in-
crease in Aβ42 levels and 55% increase in Aβ40 levels in
the SDS extractable Aβ levels (Figure 2, F) respectively
and 76% increase in Aβ42 levels and 62% increase in
Aβ40 levels in the formic acid extractable Aβ levels re-
spectively (Figure 2, G). Interestingly, the number of
Thioflavin S stained “cored” plaques in the hippocampus
of mIL-4 expressing mice (15.2% increase) did not in-
crease significantly compared to controls (Figure 3, A-C).
We next investigated whether the increase in Aβ was due
to changes in APP expression, APP processing, ApoE levels
or phagolysosomal dysfunction. Neither APP expression
nor CTFα expression or CTFβ levels were altered in mIL-4
expressing TgCRND8 mice compared to controls (Figure 4,
A-B). We additionally tested for the levels of endogenous
mouse prion protein as the mutant human APP transgene
is expressed from mouse prion promoter [22]. No signifi-
cant change in prion protein levels was apparent between
the mIL-4 expressing transgenic mice brains and control
cohorts (Figure 4, C-D). Additionally, no change in mouse
endogenous APP levels or CTFα levels were seen in
5 month old mIL-4 expressing wild type B6/C3H litter-
mates of TgCRND8 mice injected in the cerebral ventricles
on day P2 (Figure 4, E-F), suggesting that mIL-4 does not
change either the holo-APP levels or APP processing or
prion promoter expression in vivo. Though inflammatory
signaling can modulate apoE levels through modulation of
Erks [23], no significant change in ApoE levels were seen
in mIL-4 injected compared to control transgenic APP
mice (Additional file 2: Figure S2, A-B). Autophagic-
lysosomal dysfunction may lead to increased accumulation
Figure 1 AAV2/1 mediated expression of mIL-4 in TgCRND8 mice results in M2 phenotype. A-D. rAAV2/1-mIL-4 or rAAV2/1-EGFP (Control)
was injected into the hippocampus of 4 month old TgCRND8 mice and analyzed after 6 weeks. Representative images of GFAP immunoreactivity
in paraffin embedded whole brain sections (A, C) and higher magnification of the hippocampus (B, D) is shown. Scale Bar, 600 μm (A, C) and
25 μm (B, D). (n= 5-6/group). E-H. Representative images of Iba-1 immunoreactivity in paraffin embedded sections of 5.5 month old TgCRND8
mice injected with rAAV2/1 mIL-4 or rAAV2/1-EGFP (Control). Whole brain sections (E, G) and the corresponding hippocampus (F, H) are shown.
Scale Bar, 600 μm (E, G) and 25 μm (F, H). (n= 5-6/group). I. Densitometric analysis of GFAP and Iba-1 immunostaining is shown. The hippocampal
region was selected and Aperio “positive pixel count” program was used to measure percent positivity by averaging intensity of positive staining
in the annotated region. (n= 4/group; p> 0.05, t test). Data represents mean± sem. J-K. Representative immunoblot (J) and densitometric analysis
of normalized levels of GFAP and cd11b (K) obtained from 5.5 month old TgCRND8 mice injected with rAAV2/1 mIL-4 or rAAV2/1-EGFP (n = 5/
group; p> 0.05, t test). Data represents mean± sem. L. Expression of glial activation markers and cytokines were determined in 5.5 month old
mIL-4 expressing TgCRND8 mice compared to EGFP expressing age-matched controls using real time Q-PCR. Data, expressed as relative levels of
mRNA expression, represents averaged fold change values obtained from mIL-4 expressing mice, relative to averaged values obtained from EGFP
expressing mice. (n= 4/group; *p< 0.05, t test). Data represents mean± sem.
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IL-4 and IL-13, have been shown to inhibit autophagy [25],
we tested whether changes in autophagic response may ac-
count for increased Aβ accrual in mIL-4 expressing mice.
No significant changes in the autophagic marker LC3-Iwere seen in transgenic TgCRND8 mice injected with
AAV2/1-mIL-4 (Additional file 3: Figure S3, A, D), though
a nonsignificant lowering trend was observed in the non-
transgenic cohort (Additional file 3: Figure S3, B, D). We
were unable to detect LC3-II in the lysates, making it
Figure 2 Increased Aβ deposition in AAV1-mIL-4 expressing TgCRND8 mice. A-D. 4 month old TgCRND8 mice were stereotaxically injected
in the hippocampus with either AAV1-mIL-4 (C, D) or AAV1-EGFP (A, B) and sacrificed after 6 weeks (n= 5-6/group). Representative brain sections
stained with 33.1.1 antibody (pan Aβ 1–16) depict increased Aβ deposition in mIL-4 expressing mice (C, D) compared to controls (A-B) in the
immediate vicinity of the injection site. Scale Bar, 150 μm. E. Aβ plaque burden analysis shows a significantly increased amyloid deposition in
mIL-4 injected mice compared to control EGFP injected mice (n= 5/group). (*p< 0.05, t test). Data represents mean± sem. F-G. Biochemical
analyses of Aβ42 and Aβ40 levels by ELISA show significantly increased SDS (F) and formic acid (G) extractable Aβ levels in mIL-4 injected mice
compared to controls (n= 5/group). (*p< 0.05, t test). Data represents mean± sem.
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in vivo. p62 (or sequestosome-1), which is a central player
in autophagy was found to be decreased by 47% in mIL-4
expressing mice (Additional file 3: Figure S3, C-D).
A basic tenet of the amyloid cascade hypothesis is that
Aβ accumulation triggers the onset and severity of neu-
rodegenerative pathology, including tau hyperphosphor-
ylation. Though occasional CP13 immunoreactive glial
cells were visible in both mIL-4 and control mice, mIL-4
mice did not lead to appearance of phosphorylated CP13
immunoreactive tau (phospho Ser202/Thr205) in the
hippocampal neurons in TgCRND8 mice, (Additional file
4: Figure S4, A-B). Immunoblotting also failed to showany detectable levels of CP13 or MC6 (phospho Ser235)
or PHF1 epitope (phospho Ser396/Ser404) in both
cohorts (data not shown).
To further investigate the mechanism of mIL-4
induced Aβ accumulation, we treated primary wild type
mouse neuroglial cultures with rAAV2/1-mIL-4 for
72–80 hours. Analysis of the conditioned media of these
cells revealed increased mIL-4 protein (p< 0.01, t test)
but no increases in mIL-6 (data not shown) or mIFN-γ
protein compared to control cultures (Figure 5, D). In
addition, primary cultures transduced with mIL-4
showed increased levels of nuclear phosphorylated
STAT6 compared to mIFN-γ or untreated cultures
Figure 3 No significant change in cored plaques seen in AAV1-
mIL-4 expressing TgCRND8 mice. A-B. Representative fluorescent
images of Thioflavin S stained hippocampi from 5.5 month old
TgCRND8 mice injected with rAAV2/1 mIL-4 (B) or rAAV2/1-EGFP
(Control). Scale Bar, 200 μm. C. A comparison of the total number of
Thioflavin S stained “cored” plaques from the forebrain of 5.5 month
old TgCRND8 mice injected with rAAV2/1 mIL-4 or rAAV2/1-EGFP is
depicted. Data represents mean± sem. (n= 5/group; p = 0.0542, t
test).
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increased mIL-4 (4.5e3 x) levels as well as increased
levels of cd11b (6 x), scavenger receptor A (3.3 x) and
scavenger receptor B1 (15.6 x) (Figure 5, E). No signifi-
cant changes in mouse APP, BACE1, or Aβ degrading
enzymes (IDE or Neprilysin) were seen (Figure 5, E).
Since increased cd11b and scavenger receptors may re-
sult in altered phagocytic potential of mIL-4 expressing
glia, we performed phagocytosis assays on mouse pri-
mary glia and astrocytes treated with medium alone or
recombinant mIL-4. Since Aβ40 and Aβ42 can have dif-
ferent effects on phagocytosis, we used both to test out
how mIL-4 affects astroglial phagocytois. Primary mouse
glia were treated with recombinant cytokines or vehicle
for 10 hours, and fresh media added before incubation
with fluorescent Aβ for different times (Figure 6, Add-
itional file 5: Figure S5– Additional file 6: Figure S6).
These experiments were performed with cultures con-
taining >95% CD45 and Cd11b immunopositive glia
(Additional file 5: Figure S5, A-B). Initial microscopic
examination showed a decrease in the levels of interna-
lized Aβ40 in mIL-4 treated microglia following 15 min,
30 min or 60 min incubation with Aβ40-555 nm
(Additional file 6: Figure S6, A-I). This was confirmed by
flow cytometric analysis which showed a significant de-
crease in internalized fluorescent Aβ40 in mIL-4 treatedmicroglia at these three different timepoints (15 min:
-19%; 30 min: -38%; 60 min: -19%) (Figure 6, A;
Additional file 5: Figure S5, D-L). Since we have previ-
ously shown that mIL-6 treatment augments microglial
Aβ phagocytosis [10], we included this as an internal
control for Aβ40 internalization in the flow cytometric
assay (15 min: +29%; 30 min: +13%; 60 min: +41%)
(Figure 6, A; Additional file 5: Figure S5, J- L). Immuno-
blotting of microglial cells following Aβ40 phagocytosis
also showed that mIL-4 treated glia take up Aβ less effi-
ciently (Additional file 5: Figure S5, M-N). In order to
test whether fibrillized Aβ42 (fAβ42) has a different ef-
fect on glial phagocytosis, we performed phagocytosis
assays using Aβ42 fibrils (Figure 6B). Flow analysis
shows that neither mIL-6 (15 min: +25.7%; 30 min:
+28%; 60 min: +8%) nor mIL-4 (15 min: +0.53%; 30 min:
+8.1%; 60 min: +10.4%) significantly affects fAβ42
internalization by microglia (Figure 6B). Since IL-4 can
potentially activate astrocytic internalization of Aβ, we
performed phagocytosis with murine astrocyte cultures
(Figure 6, C-D). Overall, neonatal astrocytes were very
inefficient in internalizing Aβ40 as shown earlier [2,26].
Flow cytometric analysis shows that mIL-4 does not sig-
nificantly alter astrocytic Aβ40 phagocytosis (15 min:
+39.5%; 30 min: +50%; 60 min: +12.2%) (Figure 6, C)
whereas mIL-6 increases astrocytic Aβ40 internalization
significantly at all timepoints tested (15 min: +83.1%;
30 min: +58.3%; 60 min: +85.2%) (Figure 6, C). On the
other hand, mIL-4 (15 min: -16.8%; 30 min: +3%) as well
as mIL-6 (15 min: -48.4%; 30 min: -26%) has negligible
effects on astrocytes phagocytosing fAβ42 at the two
earlier timepoints tested (Figure 6, D). Only at the last
timepoint tested, i.e., following 60 min of incubation of
fAβ42, both mIL-4 (60 min: +44.4%; p< 0.05, 1 way
Anova) and mIL-6 (60 min: +45%) enhances fAβ42 up-
take by primary astrocytes (Figure 6, D).
Discussion
We have found that overexpression of mIL-4 in the
hippocampus of plaque-depositing APP CRND8 mice
increased Aβ plaque pathology. We extensively investi-
gated the likely factors that could be responsible for the
effects of mIL-4 expression on increased Aβ burden
in vivo. APP, APP CTF, BACE, ApoE and Aβ degrading
enzyme levels did not appear to be altered. As IL-4 has
been reported to inhibit autophagy [27], we investigated
LC3I/II levels, but this was not informative, as we could
not reliably detect LC3II. Levels of another key regulator
of autophagy, p62, were decreased by mIL-4. As p62 has
pleiotropic functions in addition to its role in autophagy
[28] the significance of this finding is unclear. Further-
more if autophagic pathways were being inhibited, p62
would be expected to increase, not decrease. Given i)
that these data indicating that mIL-4 does not appear to
Figure 4 mIL-4 does not affect human APP transgene expression or CTF production. A-B. Representative anti CT20 immunoblot showing
no significant changes in APP, CTFα and CTFβ levels in AAV1-mIL-4 expressing TgCRND8 compared to age-matched controls (A). Intensity
analysis (mean± sem) of anti CT20 immunoreactive APP and CTFα levels was normalized to β-actin in TgCRND8 mice cohort (B). (n= 5/group;
p> 0.05, t test). C-D. Representative immunoblot showing no significant changes in prion protein levels in AAV1- mIL-4 TgCRND8 compared to
age-matched controls (C). Intensity analysis of immunoreactive prion protein levels (mean± sem) was normalized to β-actin (D). (n= 5/group;
p> 0.05, t test). E-F. Representative anti CT20 immunoblot showing no significant changes in APP and CTFα in 5 month old AAV1-mIL-4
expressing wild type B6/C3H mice compared to age-matched controls (E). Intensity analysis of anti CT20 immunoreactive APP and CTFα levels
(mean± sem) was normalized to β-actin in wild type mice cohort (F). (n=5/group; p> 0.05, t test).
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chaperones or degrading enzymes and ii) that we and
others have previously linked proinflammatory activation
of microglia to reduced plaque burdens and enhanced
microglial scavenging of Aβ [10,11,13,14,17,29,30], we
hypothesize that mIL-4 increases Aβ burden via reduc-
tions in glial scavenging of Aβ. We explored this hypoth-
esis through Aβ internalization studies in primarymicroglia and astrocytes cultures. These studies do show
that mIL-4 abrogates soluble Aβ40 uptake by microglia
without affecting aggregated fAβ42 phagocytosis. Add-
itionally, mIL-4 does not affect the uptake of soluble or
aggregated Aβ by astrocytes, though on longer incuba-
tion, there was an increasing trend in Aβ ingestion by
the astrocytes. Given the low number of astrocytes in-
ternalizing Aβ and the fact that astrocyte cultures may
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whether astrocytes by themselves have a critical role in
Aβ phagocytosis.Figure 5 (See legend on next page.)Microglia can scavenge Aβ via receptor-mediated
phagocytosis as well as macropinocytosis [26]. In vivo
imaging techniques have demonstrated that microglia
(See figure on previous page.)
Figure 5 Characterization of rAAV2/1-mIL-4 treated primary wild type mouse neuroglial culture. A-D. rAAV2/1-mIL-4 or rAAV2/1-mIFN-γ
(2x108 viral genomes) was used to transduce primary mouse neuroglial cultures for 60 hrs in chamber slides. Upregulation of phosphorylated
STAT6 (568 nm; red fluorescence) could be seen in mIL-4 expressing cultures (C) but not in mIFN-γ expressing cultures (B) or untreated culture
containing no viruses (A). MAP2 (488 nm; green) and DAPI (350 nm, blue) were used to depict neuronal processes and nucleus respectively. mIL-
4 and mIFN-γ expression in these cultures was verified by ELISA from media collected from respective cultures (D). Magnification, 400x. (*p< 0.05,
t test). E. Expression of mouse endogenous APP, BACE1, IDE and neprilysin levels are unchanged in rAAV2/1-mIL-4 expressing primary mixed
neuroglial cultures compared to untreated control cultures using real time Q-PCR. mIL-4 expression augments scavenger receptors and cd11b
levels. Data, expressed as relative levels of mRNA expression, represents averaged fold change values obtained from mIL-4 expressing mice,
relative to averaged values obtained from EGFP expressing mice. Data for mIL-4 RNA is plotted on the left x-axis while the rest of the data are
plotted on the right x-axis. Data is representative of two independent experiments (t test, *p< 0.05). Data represents mean± sem.
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Aβ [31]. Microglial interaction with Aβ occurs through
several cell surface receptors, for example, SR-A, SR-B,
integrins and Toll-like receptors [15,32-34]. Previous
studies have noted that inflammatory cytokines decrease
scavenger receptors levels in microglial cell lines andFigure 6 Differential effect of cytokines on Aβ40 and fAβ42 uptake b
decreases microglial uptake of Aβ40 (A) but does not affect fAβ42 uptake (
significantly alter fAβ42 uptake (B). Primary mouse glia were treated with re
Aβ42-Hilyte555 for 15 min, 30 min and 60 min. Trypsinized cells were coun
additives were excluded by gating to yield the percentage of fluorescent c
representative of three independent experiments. (*p< 0.05, One way Ano
treatment does not affect astrocytic uptake of Aβ40 (C) but increases fAβ42
astrocytic Aβ40 uptake (C) and only enhances fAβ42 uptake after 60 min in
recombinant cytokines for 10 hrs and incubated in Aβ40-Hilyte555 or Aβ42
counted using Accuri6 flow cytometer. Unstained cells and labeled additive
Inset depicts GFAP/DAPI labeled astrocyte (C). Results are representative of
Tukey’s post test). Data represents mean± sem.inhibit Aβ uptake [35]. We find that mIL-4 expression
leads to increased SRs in mixed neuroglial cultures, but
this appears to be linked to modest inhibitory effects on
soluble, but not aggregated, Aβ uptake by microglia.
Therefore, it is possible that in the absence of inflamma-
tory mediators, these cells are not competent for Aβy primary mouse glia and astrocytes. A-B. mIL-4 treatment
B). mIL-6 increased microglial Aβ40 uptake (A) but does not
combinant cytokines for 10 hrs and incubated with Aβ40-Hilyte555 or
ted using Accuri6 flow cytometer. Unstained cells and labeled
ells in the mix. Inset depicts cd11b/DAPI stained glia (A) Results are
va with Tukey’s post test). Data represents mean± sem. C-D. mIL-4
uptake after 60 min incubation (D). mIL-6 consistently increases
cubation (D). Primary mouse astrocytes were treated with
-Hilyte555 for 15 min, 30 min and 60 min. Trypsinized cells were
s were excluded by gating to yield the percentage of fluorescent cells.
two independent experiments. (*p< 0.05, One way Anova with
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receptors [36,37]. Indeed, microglia were found to re-
quire stimulation with cytokines or opsonins for intern-
alizing and degrading Aβ efficiently in amyloid
vaccination paradigms [38]. Microglial populations from
human AD brains display an IL-4/IL-13 induced alter-
nate activation profile [39] as well as increased IL-1β,
suggesting that an imbalance between the inflammatory
“classical” and anti-inflammatory alternate activation
profiles may result in a dysfunctional glial response and
“failed” phagocytosis. Although speculative, these studies
may have relevance to human therapy. Many studies
show an association of nonsteroidal anti-inflammatory
drugs (NSAIDS) use with reduction of dementia risk
[40]. However, in the Adult Changes in Thought (ACT)
study, there was an increased incidence of all-cause de-
mentia and AD dementia in individuals with heavy non-
selective NSAID use, and this was associated with an
increase in neuritic plaques at autopsy [41]. Our data
could provide an explanation for this association.
It is generally accepted that an altered innate immune
response is an inherent feature of AD and most, if not
all, degenerative, CNS proteinopathies [42]. Though a
large body of literature on this subject refers to this
altered immune response as “pathogenic” or “harmful”,
in many cases this relationship is assumed and has not
been formally proven. Increased pro-inflammatory cyto-
kines levels (TNFα, Interleukin-6, Interleukin-1β), com-
bined with decreased levels of anti-inflammatory
cytokines (Interleukin-10), have been correlated with
cognitive deficits suggesting that early inflammatory
changes may be detrimental [43]. Furthermore proin-
flammatory stimuli have been linked to overt neuronal
degeneration [44]. Although proinflammatory factors
may have a detrimental role on neuronal function, prim-
ing of CNS microglia and possibly astrocytes by accumu-
lating Aβ, may be an essential innate host response that
triggers glial phagocytosis activity and clears Aβ depos-
its. Indeed, we and others have previously shown that
activation of the innate immune signaling pathways can
attenuate Aβ accumulation in APP transgenic mice and
alter the disease process [10-14,17,29,30].
mIL-4 has been shown to enhance Aβ phagocytosis in
primary rodent glial cultures in vitro [45,46]. Based
largely on such evidence, promotion of a glial M2
phenotype has been proposed to be beneficial in preclin-
ical AD models and this concept was directly supported
by one recent study, using a similar AAV mediated IL-4
expression paradigm as used in this present study [4]. In
this study IL-4 induced a Th2 like glial phenotype, but
in contrast to our results, Kiyota et al, showed that IL-4
expression in the hippocampus led to mitigation of Aβ
pathology and improved behavior in APP/PS1 mice [4].
Inherent differences in transgenic mice as well asexperimental paradigms may underlie the disparate
observations. It is possible that presenilins may regulate
cytokine secretion [47], and mutant PS1 especially may
confer altered sensitivity to immune challenges in the
resident glial cells [48]. Additionally, the two studies
were distinct with respect to initiation of treatment.
Kiyota and colleagues performed a primary prevention
study in which IL-4 expression was initiated in the pre-
deposition phase, whereas IL-4 expression in our studies
was initiated in mice with modest levels pre-existing pla-
ques. In any case, additional studies of both IL-4 and
other anti-inflammatory factors will be required to ad-
dress this discrepancy and the generalizability of this
finding.
Conclusion
In summary, we demonstrate that focal overexpression
of mIL-4 in APP transgenic mouse brains leads to exa-
cerbated Aβ plaque pathology. As these results are op-
posite of effects observed with proinflammatory
cytokines, we would suggest that the underlying mech-
anism appears to be at least in part a failure of glia to
successfully clear Aβ. Our data points to the complex re-
lationship between microglial phenotype and the final
functional outcome, necessitating a more cautious and
thorough examination of potential anti-inflammatory
therapies for AD.
Methods
Mice. All animal husbandry procedures performed were
approved by the Institutional Animal Care and Use
Committee.
AAV1 preparation and injection. AAV1 viruses expres-
sing mIL-4 or EGFP, under the control of the cyto-
megalovirus enhancer/chicken β actin promoter were
generated as described previously [19]. For stereotaxic
injections, TgCRND8 mice (n = 6/group) were anesthe-
tized with 1.5% isoflurane in 1% oxygen and secured into
a Kopf apparatus (Model 900 Small Animal Stereotaxic
Instrument, David Kopf Instruments). The coordinates
for injection were −1.7 caudal, -1.6 lateral and −1.2 ven-
tral from the bregma. A UMP2 Microsyringe Injector
and Micro4 Controller (World Precision Instruments,
USA) was used to inject 2 μl (1010 viral genomes) of
virus at a constant rate over a 10 minute period. After
allowing an additional 10 minutes, the needle was raised
and the scalp incision was closed aseptically. Nontrans-
genic mice used in the study were injected with rAAV2/
1-mIL-4 on day P2 into the cerebral ventricles and aged
till 5 months of age.
Quantitative real-time PCR. Total RNA from mice
hippocampus or primary wild type mouse neuroglial cul-
tures was isolated using the RNaqueous kit (Ambion)
and reverse transcribed using Superscript III (Invitrogen).
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followed by 40 amplification cycles of 95 °C /15 s and
60 °C/ 1 min) was performed with ABI Prism 7900 Real
Time PCR System (Applied Biosystems) using SYBR
Green to detect the amplification products. Relative
quantification of mRNA expression was calculated by the
ΔCT method described by the manufacturer (ABI Prism
7700 Sequence Detection System, User Bulletin #2) after
adjusting the levels to the corresponding internal actin
control for each sample. Primers and probes were
designed following Roche Universal Probe Library
sequences (Hoffmann-La Roche, Germany).
Preparation of brain homogenate for immunoblotting
and Aβ ELISA assay. Brain were coronally dissected
1 mm anterior and posterior to the point of injection
and used for subsequent analysis. Thus, the samples for
immunoblotting were obtained by dissecting the hippo-
campus and overlying cortex and thalamus of injected
brains. Protein samples (RIPA soluble or 2% SDS sol-
uble) separated on Bis-Tris 12% XT gels (Bio-Rad, USA)
were probed with the antibody CT20 (anti-APP
C-terminal 20 amino acid; T. E. Golde; 1:1000); 82E1
(IBL, 1:500), Prion (Abcam; 1:1000); LC3 (MBL; 1:500;
Cell Signaling, 1:250; Novus, 1:500); p62 (Cell Signaling,
1:250), CP13 (P. Davies; 1:500) and anti β-actin
(Sigma,1:1000). Relative band intensity was quantified
using ImageJ software (NIH).
Aβ levels were determined biochemically using human
Aβ end-specific sandwich ELISA as previously described
[19] on samples sequentially extracted with RIPA buffer,
2% SDS and 70% Formic Acid. All ELISA results were
analyzed using SoftMax Pro software (Molecular
Device).
Immunohistochemical imaging and image processing.
Brains were coronally dissected at the point of injection
for analysis. Immunohistochemical staining was done
using pan Aβ antibody 33.1.1 (1:1500, T. Golde), 82E1
(1:500, IBL), Iba-1 (1:1000; Wako), GFAP (1:500; Chemi-
con), pSTAT6 (1:500, Cell Signaling) and MAP2 (1:1000;
Chemicon). 1% Thioflavin S (Sigma) staining was done
on paraffin embedded brain sections using established
protocols.
Immunohistochemically and fluorescent stained sec-
tions were captured using the Aperio Scanscope XT or
FL image scanner and analyzed using either Aperio posi-
tive pixel count or ImageJ program. Brightness and con-
trast alterations were applied identically on captured
images using Adobe Photoshop CS3.
Quantification of Aβ deposition and gliosis. Parafor-
maldehyde fixed paraffin embedded brain tissue sections
were immunostained with 33.1.1 antibody. Aβ plaque
burden and intensity of astrogliosis staining was calcu-
lated using the Positive Pixel Count program (Aperio).
At least three sections per sample, 30 μm apart, wereaveraged by a blinded observer to calculate plaque bur-
den. For Thioflavin S quantitation, one section per sam-
ple was used by a blinded observer to manually count
the plaques using Adobe Photoshop CS5.
Primary murine culture and microglia/astrocyte
phagocytosis assay. Primary microglia, astrocytes or
neuronal cultures (mixed with astrocytes) were obtained
from cerebral cortices of wild type neonate mice as
described previously [38]. Glial and astrocytic cultures
typically were >90% cd11b (cd11b-APC; 1:200, BD Bios-
ciences) or GFAP (Sigma, 1:500) immunopositive re-
spectively. For phagocytosis assays, microglia or
astrocytes, pre-treated with mIL-4 (R&D Systems, USA;
5 ng/ml for 10 hours) or mIL-6 (R&D Systems, USA;
10 ng/ml for 10 hours) were incubated with 0.5 μM
Hilyte555-Aβ40 (Anaspec, USA) or fibrillar Hilyte555-
Aβ42 (Anaspec, USA). Recombinant fluorescent Aβ was
resuspended in DMSO to 1 mg/ml and diluted in
DMEM medium to 0.5 μM before addition to cells.
Hilyte555-Aβ42 was fibrillized at 370 C for 6 hours in
PBS. Cells were analyzed at three timepoints following
addition of Aβ to the culture at 370 C: 15 min, 30 min
and 1 hr. Cells were washed, gently trypsinised to re-
move cell surface associated fluorescent entities, fixed in
paraformaldehyde and mounted in DAPI containing
medium for visualization. Fluorescence intensity of indi-
vidual cells from at least 5 or more fields of views per
sample were calculated from Image J and averaged. For
FACS analysis, following washes, cells were collected by
trypsinization and resuspended in FACS buffer contain-
ing BSA and scanned. Scans were collected using
Accuri6 and analyzed with FCS Express 4 Flow Research
(BD Biosciences). Neuronal cultures were transduced
with AAV (mIL-4 or mIFN-γ; 108 viral genomes) on day
7 for 60 hours and fixed with paraformaldehyde for sub-
sequent immunocytometry. Cytokine ELISA was per-
formed using BD Bioscience OptiEIA reagents.
Statistical analysis
One-way Anova (with Tukey’s post-hoc test) or two-
tailed Student's t test was used for statistical comparison
(SigmaStat 3.0 version). Graphical analyses were done
using Prism 4 (GraphPad Software) and final images cre-
ated using Photoshop CS2 (Adobe).
Additional files
Additional file 1: Figure S1. rAAV2/1-EGFP expression in TgCRND8
mice hippocampus. A-I. Representative image obtained from mice
stereotactically injected with AAV2/1-EGFP in the hippocampus. 4 month
old TgCRND8 were injected into the hippocampus and analyzed after
6 weeks. Representative images of EGFP immunoreactivity on paraffin
embedded whole brain section (A), cortex (B), hippocampal CA neurons
(C-E), midbrain, (F), cerebellum (G), thalamus (H) and olfactory bulb (I) are
shown. Representative hippocampus from uninjected mice is shown as
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http://www.molecularneurodegeneration.com/content/7/1/36control (A, inset). I-V, cortex layers I to V; CC, corpus callosum; Sp, Septum;
Th, thalamus. Scale Bar, 600 μm (A) and 85 μm (B-I).
Additional file 2: Figure S2. mIL-4 expression does not alter ApoE
levels. A-B. No significant change in ApoE levels was seen in the
hippocampus of mIL-4 expressing 5.5 month old transgenic CRND8 mice
or age-matched control cohorts (A). Intensity analysis of ApoE levels was
normalized to β-actin (B). (n= 5-6/group; t test, p> 0.05).
Additional file 3: Figure S3. mIL-4 expression does not alter levels of
the autophagic marker LC3 but decreases p62 protein levels. A-B. No
significant change in the autophagic marker (microtubule-associated
protein light chain 3, LC3) was seen in mIL-4 expressing 5.5 month old
transgenic CRND8 mice (TG, A) or nontransgenic 5 month old
nontransgenic cohorts (NTG, B). C. p62 protein levels decrease in mIL-4
expressing 5.5 month old transgenic CRND8 mice (TG). D. Intensity
analysis of anti LC3 and p62 immunoreactive band after normalization to
β-actin immunoreactivity. (n= 4-6/group). (*p< 0.05; t test).
Additional file 4: Figure S4. mIL-4 expression does not alter levels of
phosphorylated tau. No significant change in phosphorylated tau (using
CP13 antibody) was seen in the hippocampus of mIL-4 expressing
5.5 month old transgenic CRND8 mice (B) or age-matched control
cohorts (A). Occasional CP13 immunoreactivity was seen in glial cells in
the pyramidal layer of the hippocampus (inset). Scale Bar, 150 μm (A, B)
and 25 μm (inset). (n= 6/group).
Additional file 5: Figure S5. Analysis of primary mouse microglial
culture following Aβ40 phagocytosis. A-B. Representative flow cytometric
analysis of unstained (A) and CD45-FITC stained mouse microglia (B). Glial
populations used for subsequent phagocytosis experiments were >95%
positive for both CD45 and cd11b. Inset in A depicts a representative
unstained primary mouse glial culture. Magnification, 200x. C-L. Primary
mouse glia were stimulated with medium alone (Control; D-F) or
recombinant mIL-4 (5 ng/ml; G-I) or mIL-6 (10 ng/ml; J-L). After 10 hrs of
stimulation, cells were incubated with fluorescent Aβ40 for 15 min (D, G,
J), 30 min (E, H, K) or 60 min (F, I, L). Cells were trypsinized for the
analysis of internalized fluorescent Aβ40 (D-L) by FACS. Unstained cells
and additives have been gated for exclusion (C). Representative data
from three independent experiments have been shown. Quantified data
has been plotted in Figure 6A. M-N. Immunoblot analysis to detect
presence of Aβ in primary glial cells at different timepoints following
Aβ40 phagocytosis in the presence or absence of mIL-4 (M). Intensity
analysis of 82E1 immunoreactive Aβ monomer after normalization to β-
actin immunoreactivity has been shown (N). Representative data from
two independent experiments have been shown.
Additional file 6: Figure S6. Microscopic analysis of Aβ40 phagocytosis
by mIL-4 treated mouse primary glia. Primary mouse glia were treated
with 5 ng/ml mIL-4 for 10 hrs and incubated with fluorescent Aβ40 for
0 min (A-B), 15 min (C-D), 30 min (E-F) or 60 min (G-H). Following gentle
trypsinization, cells were fixed, stained with the nuclear stain DAPI and
visualized. Inset (C) depicts mIL-6 treated glia after 15 min incubation
with Aβ40. Quantitation of average fluorescent count is depicted (I).
Magnification, 400x. (*p< 0.05; t test).Abbreviations
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